title: Pharmacotherapy: inhibiting LV remodeling—the need for a targeted approach.
authors: Jay N
authors: JN
authors: Cohn
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000577:Amides / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005650:Fumarates / Q000627:therapeutic use; D006801:Humans; D058990:Molecular Targeted Therapy; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology*; D016032:Randomized Controlled Trials as Topic; D012083:Renin / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects*; D016896:Treatment Outcome; D020257:Ventricular Remodeling / Q000187:drug effects*; D000092502:Renin Inhibitors
chemical_list: D000319:Adrenergic beta-Antagonists; D000577:Amides; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D005650:Fumarates; D012083:Renin; D000092502:Renin Inhibitors; C446481:aliskiren